Astellas Pharma US, Inc. company's primary products include organ transplant immunosuppressant Prograf, overactive bladder treatment VESIcare, and vascular dilator Andenoscan. It is focusing its efforts on the following therapeutic areas: cardiology, dermatology, immunology, infectious diseases, and urology. The company's other products include antifungals Mycamine and AmBisome, enlarged prostate treatment Flomax, and dermatological product Protopic. Astellas Pharma US is a subsidiary of Astellas Pharma, which was formed in 2005 with the merger of Japan-based pharmaceutical companies Yamanouchi and Fujisawa.

MannKind Corporation was founded in 1991 and is headquartered in Valencia, California. MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidate, AFRESA, a rapid-acting insulin that has completed phase 3 clinical trials for the treatment of diabetes in the United States, Europe, and Japan. The company's lead product candidates also include MKC1106-PP, which is in phase I clinical trial for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, non-small cell lung and prostate carcinomas, glioblastoma, and melanoma.

BioTime, Inc. company was founded in 1990 and is headquartered in Alameda, California. BioTime, Inc. is a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. The Company’s operating revenues have been generated primarily from licensing fees related to the sale of its plasma volume expander products, primarily Hextend. The company began to make its first stem cell research products available during the year ended December 31, 2008, but it had not yet generated significant revenues in that business segment.

VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California. VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the research and development of compounds for the treatment cardiovascular and metabolic diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its principal product, VIA-2291, is in Phase II clinical trials in patients with acute coronary syndrome and patients with stenosis of the carotid artery. The company has agreements with Hoffmann-LaRoche Inc. and Hoffmann-LaRoche Ltd. to develop and commercialize two sets of compounds for the treatment of cardiovascular and metabolic disease.

The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Its flagship products - experimental drugs AEGR-733 and AEGR-427 - are MTP (microsomal triglyceride transfer protein) inhibitors, drugs which block a protein that incites cholesterol production in the liver and intestine. Cutting LDL levels may add years to patients' lives but must be weighed against potential side effects such as fat accumulation in the liver, which can lead to inflammation, scarring, and cirrhosis.

Kyorin, founded in 1923, already has affiliates and subsidiaries in Germany and the US. KYORIN Co., Ltd. is a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sale of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the manufacture of clinical testing products, as well as the research of new drugs and candidate compounds. The Others segment is involved in the development and sale of cosmetics, as well as raw materials of medicines and cosmetics, the promotion of sales, the planning and production of advertisements, the sale of packaging materials, in addition to the provision of advisory services and the operational management of funds.

Instrumentation Laboratory Company develops and manufactures diagnostic medical equipment primarily for hospitals and clinical laboratories around the globe. The company provides critical care systems, hemostasis products, and information management services. Its product lines include GEM and Synthesis analyzers for critical care diagnostics, and ACL and HemosIL analyzers and reagents for automated clot-timing testing. Its products are marketed through global affiliates and third-party distributors. Instrumentation Laboratory was established in 1959 and is a division of private Spanish health care company Werfen Group.

CPEX Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, licensing, and commercialization of pharmaceutical products utilizing its validated drug delivery technology. Its drug delivery technology, CPE-215 technology, enhances permeation and absorption of pharmaceutical molecules across biological membranes such as the skin, nasal mucosa and eye. The company's principal product Testim, a gel for testosterone replacement therapy is licensed to Auxilium Pharmaceuticals, Inc. that markets the product in the United States, Europe, and other countries. It also holds U.S. and international patents, and other proprietary rights to technologies that facilitate the absorption of drugs. In addition, CPEX Pharmaceuticals, Inc. is developing an intranasal insulin product candidate, Nasulin, which is in Phase II clinical trials. The company was incorporated in 2007 and is headquartered in Exeter, New Hampshire.

QLT Inc. company was founded in 1981 and is headquartered in Vancouver, Canada. QLT Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products, primarily in the field of ophthalmology. It offers Visudyne, a photosensitizer to treat the eye disease, known as wet age related macular degeneration; and also used for the treatment of subfoveal CNV due to pathologic myopia, or severe near-sightedness, and presumed ocular histoplasmosis or other macular diseases. The company also offers Eligard product line that includes one, three, four, and six month commercial formulations of Atrigel technology combined with leuprolide acetate for the treatment of prostate cancer. Its products in development include Visudyne therapy; punctal plug drug delivery system, an invasive drug delivery system for delivering various drugs topically to the eye through controlled sustained release to the tear film, under Phase II studies targeting the treatment of glaucoma and ocular hypertension; and QLT091001, a Phase Ia orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle, as well as OT-730, a prodrug of a beta adrenergic antagonist (a type of beta blocker) under investigation for the treatment of glaucoma.

Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, HIV, and inflammatory diseases. The company's lede program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, multiple myeloma, and prostate cancer. Incyte has several other products in clinical trial stages, including a CCR5 antagonist designed to prevent the entry of HIV into target cells.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.